Ranbaxy and Pfizer Settle Lipitor Litigation
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Ranbaxy Laboratories said on June 18 that it has settled most of the patent litigations involving Lipitor (atorvastatin) with Pfizer, putting an end to a five-year legal battle between the two companies
You may also be interested in...
Ranbaxy Launches AG Version Of Caduet As CEO Likens Lipitor Deal With Teva To An Insurance Policy
Both Ranbaxy and Mylan appear to have agreed to sell all doses of Caduet under separate authorized generic deals with Pfizer.
A Big Hit But A Small Miss? Ranbaxy’s Caduet Prospects In Doubt As Mylan Storms The Market
A rollercoaster of a week for India’s Ranbaxy ends with yet another mystery – what is the status of its first-to-file applications for Pfizer’s Caduet?
A Big Hit But A Small Miss? Lipitor Generic Launched But Ranbaxy’s Caduet Prospects In Doubt As Mylan Storms The Market
A rollercoaster of a week for India’s Ranbaxy ends with yet another mystery – what is the status of its first-to-file applications for Pfizer’s Caduet?